PolyNovo (PNV) H2 2024 earnings summary

Executive summary

• FY24 revenue reached AUD 104.8 million, up 57.5% year-over-year, with NovoSorb product sales at AUD 92 million, up 54.5%.

• Achieved first full-year net profit after tax of AUD 5.3 million, reversing a prior year loss of AUD 4.9 million, and positive operating cash flow of AUD 3.7 million.

• U.S. and Rest of World (ROW) sales saw significant growth, with U.S. up 49% and ROW up 73.3% compared to FY23.

• Expanded global presence to 41 countries, with commercial sales in 29, over 50,000 patients treated, and 284 independent articles and abstracts published.

• Record monthly sales in Q4, with April and May revenues exceeding AUD 9 million each.

Financial highlights

• BARDA revenue was AUD 11.2 million, up 97%, and total revenue including BARDA was AUD 104.8 million, up from AUD 66.5 million in FY23.

• Operating expenses increased 44.2%, demonstrating business leverage as revenue outpaced cost growth.

• Positive operating cash flow of AUD 3.7 million, with cash and cash equivalents at year-end of AUD 45.9 million.

• EBITDA improved to AUD 3.6 million from a loss of AUD 2.8 million in FY23.

• Gross margin for the group was 94%.

Outlook and guidance

• No formal revenue or profit guidance provided; focus remains on growth, global expansion, and continued investment in R&D, clinical evidence, and capacity.

• U.S. market expected to be a growth driver for the next 5-10 years; India anticipated as a major volume market.

• PMA submission for BTM targeted for November, with FDA approval expected in about a year.

• Plans for Japan market entry in CY25 and India tenders/reimbursement in FY25.

• Capex expected to rise in FY25 and FY26 for new manufacturing facility in Port Melbourne.